GlobeNewswire·Nov 6, 2026, 4:15 PM ET

Entera Announces Third Quarter 2026 Financial Results and Business Updates

Entera Bio expects first site activation for its Phase 3 EB613 osteoporosis study in late 2026.
New Phase 2 post-hoc analysis presented at ASBMR 2026 showed EB613 enhanced bone formation in patients with T-scores of -2.5 or lower.
The EB613 Phase 3 study will enroll approximately 900 postmenopausal women with a 2:1 randomization ratio to EB613 or placebo.
Topline results for the EB613 Phase 3 trial are anticipated in the second half of 2028.
Entera appointed Riccardo Paolo Camisasca as Chief Medical Officer, Michele McDermott as Senior Vice President of Medical Affairs, Ofer Spiegelstein as VP of Early Clinical Development, and Graziella Soulban as VP of Clinical Development.
Laura Hamill and Juan Camilo Arjona Ferreira, M.D. were appointed to the Board of Directors effective December 1, 2026.
IND-enabling activities are ongoing for EB612, an oral therapy for hypoparathyroidism developed with OPKO, with a Phase 1 study planned for 2027.
Cash & cash equivalents stood at $265.9 million as of September 30, 2026, following a $275 million private placement in July 2026.
R&D expenses for the quarter ended September 30, 2026, were $4.9 million, driven by EB613 Phase 3 start-up activities & the OPKO collaboration.
General & administrative expenses for the quarter were $2.3 million, while the net loss was $15.6 million.
The company's cash resources are expected to fund the EB613 Phase 3 program through topline results & NDA submission, supporting operations into 2030.